ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Allergic Rhinitis
Nasal Polyps
Rhinitis
Lung Diseases

Asthma trials near Louisville, KY, USA:

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations....

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab

Phase 2

Amgen
Amgen

Louisville, Kentucky, United States and 35 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 369 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Enrolling
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 478 other locations

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compa...

Enrolling
Asthma
Drug: FF/VI
Device: ELLIPTA

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Louisville, Kentucky, United States and 79 other locations

decline in adult patients with uncontrolled moderate to severe asthma.The estimated duration is 4±1 weeks of screening and run-in period, fo...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Phase 4

Sanofi
Sanofi

Louisville, Kentucky, United States and 214 other locations

Locations recently updated

inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma...

Enrolling
Asthma
Drug: Salbutamol HFA-152a
Drug: Salbutamol HFA-134a

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Louisville, Kentucky, United States and 100 other locations

compared to omalizumab* To evaluate the effect of dupilumab on asthma control at Week 24 compared to omalizumab* To evaluate the safety of ...

Active, not recruiting
Asthma
Chronic Rhinosinusitis With Nasal Polyps
Drug: Omalizumab
Drug: Placebo

Phase 4

Sanofi
Sanofi

Louisville, Kentucky, United States of America and 94 other locations

This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety...

Active, not recruiting
Nasal Polyposis
Biological: Benralizumab 30 mg
Biological: Matched placebo

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 115 other locations

Locations recently updated

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with CRSwNP.

Active, not recruiting
Nasal Polyps
Drug: Placebo
Biological: Depemokimab (GSK3511294)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Louisville, Kentucky, United States and 105 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems